Tech Center 1600 • Art Units: 1648 1671 1672
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18026866 | CELL-FREE ANTIBODY ENGINEERING PLATFORM AND NEUTRALIZING ANTIBODIES FOR SARS-COV-2 | Non-Final OA | Massachusetts Institute of Technology |
| 18247161 | METHODS, DEVICES, AND RELATED ASPECTS FOR DETECTING EBOLA VIRUS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18031602 | STABILIZED NOROVIRUS VIRUS-LIKE PARTICLES AS VACCINE IMMUNOGENS | Non-Final OA | Board of Regents, the University of Texas System |
| 17762360 | MODIFIED T CELLS AND METHODS OF PREPARING THE SAME | Final Rejection | The University of North Carolina at Chapel Hill |
| 18260029 | SPECIFIC DETECTION OF NUCLEIC ACID SEQUENCES USING ACTIVATE CLEAVE & COUNT (ACC) TECHNOLOGY | Non-Final OA | The Board of Trustees of the University of Illinois |
| 18043613 | METHODS TO STIMULATE HLA-AGNOSTIC IMMUNE RESPONSES TO PROTEINS USING NUCLEATED CELLS | Non-Final OA | STEMCELL TECHNOLOGIES CANADA INC. |
| 18734088 | VIRUS AND ANTIGEN PURIFICATION AND CONJUGATION | Non-Final OA | KBIO HOLDINGS LIMITED |
| 18526819 | DNA ANTIBODY CONSTRUCTS FOR USE AGAINST HIV | Non-Final OA | INOVIO PHARMACEUTICALS, INC. |
| 17779564 | TREATMENT OF DISEASES RELATED TO HEPATITIS B VIRUS | Non-Final OA | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM |
| 18010416 | SWINE INFLUENZA A VIRUS VACCINE COMPRISING A NUCLEIC ACID CONSTRUCT COMPRISING FIRST, SECOND AND THIRD NUCLEIC ACID SEQUENCES ENCODING DISTINCT NEURAMINIDASE ANTIGENS OF THE VIRUS | Non-Final OA | Intervet Inc. |
| 18002899 | EDIBLE CELL BASED VACCINES | Non-Final OA | Trustees of Tufts College |
| 18258943 | IMMUNOGENIC FORMULATION CONTAINING ONE OR MORE MODIFIED BCG STRAINS EXPRESSING A SARS-CoV-2 PROTEIN, USEFUL FOR PREVENTING, TREATING, OR ATTENUATING THE DEVELOPMENT OF COVID-19 | Non-Final OA | FUNDACION COPEC UNIVERSIDAD CATÓLICA |
| 18283061 | Application of an Immunogenic or Vaccine Composition Against COVID-19 | Non-Final OA | EYE VACC |
| 17778374 | Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer | Non-Final OA | Bavarian Nordic A/S |
| 18259841 | DEVICE AND SYSTEM FOR THE DETECTION OF ENVIRONMENTAL CONTAMINANTS | Non-Final OA | ITEL TELECOMUNICAZIONI S.R.L. (40%) |
| 18252009 | ANTIVIRAL AGENTS | Non-Final OA | Quantec Limited |
| 18032545 | FUSION PROTEIN AND VACCINE | Non-Final OA | THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY |
| 17999131 | METHOD FOR DETERMINING THE POTENCY OF ANTIGENS | Non-Final OA | Takeda Vaccines, Inc. |
| 18029374 | SARS-CoV-2 PROTEIN-DERIVED PEPTIDE AND VACCINE CONTAINING SAME | Non-Final OA | CANCER PRECISION MEDICINE, INC. |
| 18018519 | ADAPTER POLYPEPTIDES AND METHODS OF USING THE SAME | Non-Final OA | SPOT BIOSYSTEMS LTD. |
| 18000858 | METHODS TO DETECT AND TREAT SARS-COV-2 (COVID19) INFECTION | Non-Final OA | THE U.S. GOVERNMENT AS REPRESENTED BY THE DEPT. OF VETERANS AFFAIRS |
| 18061045 | AUTOLOGOUS DENDRITIC CELL VACCINE KIT AND USES | Final Rejection | AIVITA BIOMEDICAL, INC |
| 18056924 | USE OF A BIRNAVIRUS FOR THE TREATMENT OF A DISEASE CAUSED BY VARICELLA ZOSTER VIRUS (VZV) | Non-Final OA | HepC Terápia Kereskedelmi és Szolgáltató Zrt. |
| 17642570 | COMBINED EXPRESSION OF A CHIMERIC CD3 FUSION PROTEIN AND AN ANTI-CD3-BASED BISPECIFIC T CELL ACTIVATING ELEMENT | Non-Final OA | BIOTHEUS (SUZHOU) CO., LTD. |
| 17753603 | COMPOUNDS FOR THE INDUCTION OF ANTIGEN-SPECIFIC IMMUNE TOLERANCE | Non-Final OA | Anokion SA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy